The global liquid biopsy market size is expected to reach USD 7,645.0 Million in 2030 and register a revenue CAGR of 20.3% over the forecast period, according to the latest analysis by Emergen Research. Rise in demand for early cancer detection is a key factor driving global liquid biopsy market revenue growth.
Liquid biopsy is a safe and popular procedure carried out during examination of cancer. The procedure is easy and minimally invasive, allows early detection and diagnosis of cancer, and helps in identification of cancer treatment. In addition, growing popularity of non-invasive techniques is driving private and public financing for research in the field of liquid biopsy, which allow medical professionals to discover various aspects of a tumor through a patient’s blood sample. It facilitates medical professionals to understand, which treatments are suitable for patients.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/34
Global liquid biopsy Market Highlights:
- Regional demand estimation and forecast
- Product Mix Matrix
- R&D Analysis
- Cost-Benefit Analysis
- Pre-commodity pricing volatility
- Supply chain optimization analysis
- Technological updates analysis
- Raw Material Sourcing Strategy
- Competitive Analysis
- Mergers & Acquisitions
- Location Quotients Analysis
- Carbon Footprint Analysis
- Patent Analysis
- Vendor Management
Competitive Landscape:
The latest study provides an insightful analysis of the broad competitive landscape of the global liquid biopsy market, emphasizing the key market rivals and their company profiles. A wide array of strategic initiatives, such as new business deals, mergers & acquisitions, collaborations, joint ventures, technological upgradation, and recent product launches, undertaken by these companies has been discussed in the report. The report analyzes various elements of the market’s competitive scenario, such as the regulatory standards and policies implemented across the industry over recent years. Our team of experts has leveraged several powerful analytical tools, such as Porter’s Five Forces analysis and SWOT analysis, to deliver a comprehensive overview of the global liquid biopsy market and pinpoint the fundamental growth trends.
Some companies in the global market report include Bio-Rad Laboratories, Inc., Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Biocept, Inc., QIAGEN, F. Hoffmann-La Roche Ltd., MDxHealth, Menarini Silicon Biosystems, and Agena Bioscience, Inc.
Regional Landscape section of the liquid biopsy report offers deeper insights into the regulatory framework, current and emerging market trends, production and consumption patterns, supply and demand dynamics, import/export, and presence of major players in each region.
The various regions analyzed in the report include:
- North America (U.S., Canada)
- Europe (U.K., Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Key Points Covered in This Section:
- Regional contribution
- Estimated revenue generation
- Vital data and information about the consumption rate in all the leading regional segments
- An expected rise in market share
- Forecast growth in the overall consumption rate
Request customization of the report @ https://www.emergenresearch.com/request-for-customization/34
Emergen Research has segmented the global liquid biopsy market based on product type, circulating biomarkers, sample type, technology, disease, application, end-use, and region:
- Product Type Outlook (Revenue, USD Million; 2019–2030)
- Assays Kits
- Instruments
- Services
- Circulating Biomarkers Outlook (Revenue, USD Million; 2019–2030)
- Circulating Tumor DNA (ctDNA)
- Circulating Tumor Cells (CTCs)
- Extracellular Vesicles (EVs)
- Cell-Free DNA (cfDNA)
- Others
- Sample Type Outlook (Revenue, USD Million; 2019–2030)
- Blood Sample
- Urine Sample
- Others
- Technology Outlook (Revenue, USD Million; 2019–2030)
- Multi-gene-parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
- Disease Outlook (Revenue, USD Million; 2019–2030)
- Oncology
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma Cancer
- Others
- Non-cancer
- Application Outlook (Revenue, USD Million; 2019–2030)
- Early Cancer Screening
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring Orthopedics
- End-Use Outlook (Revenue, USD Million; 2019–2030)
- Hospitals & Physician Laboratories
- Reference Laboratories
- Academic & Research Centers
- Others
Report Highlights:
- Besides offering a vivid depiction of the global liquid biopsy business sphere and its fundamental operations, the latest report provides the industrial chain analysis and list down the current and future market trends and growth opportunities.
- The report includes information on the present and historical market scenarios, which helps forecast the market conditions over the next eight years (2021-2030).
- The report scrutinizes the salient factors influencing the growth of the market in the near future.
- The strategic marketing recommendations, crucial information related to the new market entrants, and expansion plans of various businesses are poised to provide the reader with a competitive edge in the market.
To know more about the report, visit @ https://www.emergenresearch.com/industry-report/liquid-biopsy-market
Thank you for reading our report. Customization of this report is available in chapter-wise or region-wise sections. Kindly get in touch with us to know more about the report, and our team will provide excellent assistance.
About Us:
At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: www.emergenresearch.com
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com